Ultragenyx Pharmaceutical (RARE): Reassessing Valuation After Recent Share Price Rebound [Yahoo! Finance]
Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? [Yahoo! Finance]
Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest [Yahoo! Finance]
Ultragenyx to Participate in Investor Conferences in December
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Barclays PLC from $81.00 to $50.00. They now have an "overweight" rating on the stock.